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The World Health Organisation estimates that approximately
one billion people are infected and up to 500 000 people die
from influenza each year.1 The greatest burden of illness usually
occurs among children, while the highest burden of severe
disease (in terms of hospitalisation and death) occurs in those
with underlying medical conditions, infants and young children,
and elderly people.2 Current circulating influenza strains in
humans include influenza A(H1N1)pdm09, influenza A(H3N2),
and both influenza B viruses (B/Victoria and B/Yamagata).3 4
This article provides non-specialists with information on how
to diagnose, manage, and prevent flu.
What is influenza virus?
There are four types of influenza viruses: influenza A, B, C,
and D,3-6 but only influenza A and B viruses cause clinically
important human disease and seasonal epidemics (table 1⇓).1
Influenza A viruses cause the most severe clinical disease and
are the commonest cause of seasonal epidemics and pandemics
in human populations.1
What are the symptoms of influenza?
Influenza is characterised by sudden onset of fever, myalgia,
headache, malaise, dry cough, sore throat, and nasal congestion
(fig 1⇓).13-15 Gastrointestinal symptoms including nausea,
vomiting and diarrhoea are also common.16 The incubation
period of influenza (time from infection to development of
symptoms) is 1 to 4 days.17 Viral shedding, when the virus is
infectious, usually occurs from one day before the onset of
symptoms, to 5-7 days after.18-20
Influenza can cause severe illness or death, particularly in high
risk populations (box 1).23Mortality is higher among individuals
with complicated influenza (illness necessitating hospital
admission, or an exacerbation of an underlying chronic illness)
across all age groups, but is highest in infants aged 6 months
or younger.2
How do influenza epidemics and
pandemics occur?
Minor changes that occur in virus proteins between influenza
seasons (known as antigenic drift) result in annual epidemics,
with winter peaks in temperate regions (November-April in the
northern hemisphere, and May-October in the southern
hemisphere, see fig 2⇓).3 In tropical and subtropical regions the
seasonality of influenza is less well defined (fig 2⇓).24 25
In contrast, pandemics (severe global epidemics) of influenza
occur when a new influenzaA subtype emerges abruptly because
of a major shift in the proteins on the virus surface (antigenic
shift), often because of combination with viruses circulating in
animals.26Asmost people have no immunity to the new subtype,
infection spreads quickly (table 2⇓).
How is influenza diagnosed?
Most influenza is diagnosed clinically in the community at times
when the virus is known to be circulating. Patients admitted to
hospital may have respiratory samples taken for testing by
polymerase chain reaction (PCR), rapid antigen test, or
immunofluorescence assay. With respiratory outbreaks in a
closed setting (such as care homes, schools, hospitals) nasal
swabs may be taken from the first few symptomatic individuals
to identify the responsible organism.
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What you need to know
• Influenza is an acute viral infection of the respiratory tract that spreads easily from person to person
• Influenza is usually self limiting in healthy individuals, with recovery in 3-7 days
• Elderly people, children under 6 months old, pregnant women, and people with chronic conditions or immunosuppression are at
increased risk of complications
• Offer influenza vaccination to people at risk of complications and increased influenza exposure, as well as to young children, who are
efficient infection spreaders
• People in high risk groups may benefit from antiviral therapy, hospitalisation, or intensive care
Box 1: Who should be prescribed antiviral treatment for influenza?*
Individuals at risk of influenza related complications
• Adults >65 years old
• Individuals with underlying chronic health conditions (chronic heart, lung, kidney, liver, neurological, and metabolic diseases, such as
diabetes)
• Individuals with reduced immunity (such as after chemotherapy, asplenia, prolonged steroid treatment, splenic dysfunction, or HIV
infection)
• Pregnant women, including up to two weeks post-partum
• Any other individual whom the clinician feels is at increased risk of developing complications from influenza
• Morbidly obese individuals (body mass index >40)
Individuals admitted to hospital with suspected or confirmed influenza
*Based on guidance from National Institute for Health and Care Excellence (NICE)21 22
What treatments are available for
influenza?
Influenza is usually self limiting in healthy individuals.
Treatment of uncomplicated disease in healthy individuals is
supportive and includes antipyretics, adequate fluid intake, rest,
and staying off work or school until 24 hours after resolution
of fever to limit spread to others.21
Most randomised trials of antiviral drugs have been conducted
among otherwise healthy individuals and have shown modest
reductions in symptom duration (0.7 days).27 Fewer studies have
been conducted among individuals at risk of complicated
influenza. Data from observational studies and trials suggests
that antiviral treatment may reduce adverse outcomes.28-30 For
example, the meta-analysis from 2015 reported fewer lower
respiratory tract complications requiring antibiotics after
oseltamivir treatment compared with placebo (risk difference
−3.8%) and fewer hospital admissions (risk difference −1.1%).30
NICE,21 Public Health England,12 UKChief Medical Officers,31
and the WHO32 recommend treatment of suspected and
confirmed influenza for individuals at risk of complicated
influenza (box 1). General practitioners considering prescription
of antivirals should discuss with patients likely benefits, as well
as possible harms including nausea (number treated to cause
nausea in one patient=28)27 and vomiting (number treated to
cause vomiting in one patient=22).27
Individuals with complicated influenza may be helped by
antiviral treatment.21 22 Treatment is most effective if started
within 48 hours of symptom onset, and it should not be delayed
while awaiting results of investigations.12 28 Neuraminidase
inhibitors oseltamivir and zanamivir inhibit viral release from
infected cells and reduce the rate of viral replication.
Meta-analysis of individual participant data found that,
compared with late treatment, early treatment (within 48 hours
of symptom onset) of hospitalised individuals with complicated
influenza reduced the odds of mortality by 52%.28 Some
individuals may require antibiotic therapy to treat secondary
bacterial infections.
How can influenza be prevented?
Vaccination
Vaccination is the most effective means of preventing influenza
and its complications. Immunity developed in one influenza
season may not provide protection in future years mainly
because of changes in circulating strains, antigenic drift, and
waning immunity. Influenza vaccines are updated annually to
include the viral strains that are predicted to circulate in winter.3 4
Box 2 lists the UK recommendations for vaccination.23
Vaccination schedules may vary internationally, and so it is
important to check local policies. In healthy adults, trivalent
inactivated vaccines have an overall vaccine efficacy of 60%.33 34
Newer quadrivalent vaccines are being increasingly adopted
due to the broader protection provided by the inclusion of an
additional influenza B virus.35-38
Since 2013, the UK influenza vaccination programme has been
extended to children aged 2-4 years, with planned phased
introduction to children of school ages,23 as it reduces morbidity
by directly protecting children and provides indirect protection
to vulnerable groups (such as grandparents) by reducing
transmission in the community.39 40 Attenuated live nasal spray
formulation is recommended in children aged 2-<17 years based
on its superior efficacy and greater immunity against
mismatched strains compared with inactivated vaccines.41-43
Studies have found that inactivated influenza vaccines cannot
cause influenza disease and are safe in pregnancy.44-47
Common side effects of vaccination include local injection site
reactions and cold-like symptoms. Fever, malaise, and myalgia
are less common.33 Contraindications include confirmed severe
allergic reaction (anaphylaxis) to a previous influenza vaccine
or to any component of the vaccine.23 Live attenuated influenza
vaccine (LAIV) should not be given to children or adolescents
with severe immunodeficiency or to those taking salicylate
treatments because of the risk of Reye’s syndrome.23 LAIV is
also not recommended for pregnant women or adults with
immunosuppression.23
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Box 2: Who is offered influenza vaccination in the UK?23
People at risk of influenza related complications*
• Adults over 65 years old
• Individuals with underlying chronic health conditions (for example, chronic heart, lung, kidney, liver, neurological, and metabolic
diseases, such as diabetes)
• Individuals with reduced immunity (such as after chemotherapy, asplenia or splenic dysfunction, or HIV infection)
• Pregnant women
• Morbidly obese individuals (body mass index >40)
People at risk of influenza exposure or transmitting influenza to vulnerable groups
• Health and social care workers
• Individuals who live with or care for vulnerable people
People living in settings where rapid spread is likely after introduction of infection, potentially resulting in high morbidity
and mortality
• Individuals living in long-stay care facilities
Efficient influenza spreaders
• Children aged 2-<17 years
*Children <6 months old are not eligible to receive influenza vaccines and should be protected against influenza through
vaccination of their mother during pregnancy.
Antiviral chemoprophylaxis
Influenza may be prevented or rendered less severe by
post-exposure prophylaxis (PEP) with antivirals (oseltamivir
and zanamivir).27 48 NICE21 and Public Health England12
recommend that, when influenza is circulating, antivirals are
offered to those who are:
• In at-risk groups (box 2) and
• Who have had close contact with people with confirmed
or suspected influenza (that is, living in the same household
or residential setting) and
• Able to start prophylaxis within 48 hours (oseltamivir) or
36 hours (zanamivir) of contact and
• Have not received vaccination in the current influenza
season, or who have been vaccinated <14 days since contact
or where there is significant mismatch between vaccine
and circulating strains, or during an outbreak in a closed
setting regardless of vaccination history.
Infection control and isolation
Although published evidence for effectiveness is limited, hand
and cough hygiene are likely to be important interventions to
reduce influenza spread in the community, as well as in closed
settings (table 3⇓).
During an outbreak, consider isolation of residents of closed
settings for the duration of the infectious period (five days after
symptom onset) to limit spread to others. Cohorting of patients
(that is, in separate hospital bays or on separate floors of a
residential home) may be necessary. Residential homes may
need to be closed to new admissions until the outbreak is
controlled. Care must be taken when discharging a patient from
a ward with a known influenza outbreak to a care home, or vice
versa.
New developments in prevention and
treatment of influenza
Vaccine candidates have recently been developed that can elicit
antibodies against multiple influenza strains, and thus could
overcome the need for annual influenza vaccines.55-57 Several
antiviral drugs are currently in development for influenza
treatment, including favipiravir,58 nitazoxanide,59 60 and
arbidol.61 62
Contributors: SG and PM conceived of the review. SG is the guarantor
of the manuscript. SG, PM, and AH undertook the literature review, and
were supported by Dr Bethan Roberts, foundation year 2 trainee in
health protection, Cheshire and Merseyside Health Protection Team,
Public Health England North West. SG, PM, and AH contributed to
writing drafts of the manuscript. PM designed and wrote code for the
interactive application. All authors have seen and approved the final
manuscript version.
Competing interests: We have read and understood BMJ policy on
declaration of interests and declare that we have no competing interests.
Provenance and peer review: Not commissioned; externally peer
reviewed.
1 World Health Organization. Influenza (seasonal)—Fact sheet No 211. 2014. www.who.
int/mediacentre/factsheets/fs211/en/.
2 Cromer D, van Hoek AJ, Jit M, EdmundsWJ, Fleming D, Miller E. The burden of influenza
in England by age and clinical risk group: a statistical analysis to inform vaccine policy.
J Infect 2014;68:363-71. doi:10.1016/j.jinf.2013.11.013 pmid:24291062.
3 World Health Organization. Global Influenza Surveillance and Response System (GISRS).
2016. www.who.int/influenza/gisrs_laboratory/en/.
4 World Health Organization. Influenza vaccine viruses and reagents. 2016. www.who.int/
influenza/vaccines/virus/en/.
5 Ferguson L, Eckard L, Epperson WB, et al. Influenza D virus infection in Mississippi beef
cattle. Virology 2015;486:28-34. doi:10.1016/j.virol.2015.08.030 pmid:26386554.
6 Hause BM, Collin EA, Liu R, et al. Characterization of a novel influenza virus in cattle and
Swine: proposal for a new genus in the Orthomyxoviridae family.MBio 2014;5:e00031-14.
doi:10.1128/mBio.00031-14 pmid:24595369.
7 A revision of the system of nomenclature for influenza viruses: a WHO memorandum.
Bull World Health Organ 1980;58:585-91.pmid:6969132.
8 Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology
of influenza A viruses. Microbiol Rev 1992;56:152-79.pmid:1579108.
9 Olson DR, Heffernan RT, Paladini M, Konty K, Weiss D, Mostashari F. Monitoring the
impact of influenza by age: emergency department fever and respiratory complaint
surveillance in New York City. PLoS Med 2007;4:e247. doi:10.1371/journal.pmed.
0040247 pmid:17683196.
10 Kawai S, Nanri S, Ban E, et al. Influenza vaccination of schoolchildren and influenza
outbreaks in a school. Clin Infect Dis 2011;53:130-6. doi:10.1093/cid/cir336 pmid:
21690619.
11 Matsuzaki Y, Sugawara K, Furuse Y, et al. Genetic Lineage and Reassortment of Influenza
C Viruses Circulating between 1947 and 2014. J Virol 2016;90:8251-65. doi:10.1128/JVI.
00969-16 pmid:27384661.
12 Public Health England. PHE guidance on use of antiviral agents for the treatment and
prophylaxis of seasonal influenza. Version 7.0. PHE, 2016.
13 Lam PP, Coleman BL, Green K, et al. Predictors of influenza among older adults in the
emergency department. BMC Infect Dis 2016;16:615. doi:10.1186/s12879-016-1966-
4 pmid:27793117.
14 Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms
predicting influenza infection. Arch Intern Med 2000;160:3243-7. doi:10.1001/archinte.
160.21.3243 pmid:11088084.
15 Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during
the influenza season.Clin Infect Dis 2006;43:564-8. doi:10.1086/506352 pmid:16886147.
16 Minodier L, Charrel RN, Ceccaldi PE, et al. Prevalence of gastrointestinal symptoms in
patients with influenza, clinical significance, and pathophysiology of human influenza
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2016;355:i6258 doi: 10.1136/bmj.i6258 (Published 7 December 2016) Page 3 of 10
PRACTICE
Sources and selection criteria
We searched PubMed and the Cochrane Library databases (search terms “influenza,” “flu,” “influenza-like illness”). We obtained information
on the epidemiology of influenza from annual reports produced by authoritative bodies and organisations such as Public Health England
(PHE), Centers for Communicable Disease Prevention and Control (CDC), and theWorld Health Organization (WHO).We reviewed up-to-date
influenza guidelines and reviews, including those published by PHE, Cochrane Reviews, and the National Institute for Health and Care
Excellence (NICE).
Education into practice
• What steps have you taken to improve the uptake of influenza vaccination among staff and eligible patients under your care?
• Have you reviewed your organisation’s infection control policy for responding to an outbreak of influenza-like illness?
• Have you reviewed antivirals prescribed (treatment or prophylaxis) for eligible patients with influenza and their close contacts?
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Tables
Table 1| Influenza viruses
At risk groupsReservoirClassificationInfluenza
type
Infects people of all ages, but
disproportionately causes severe disease in
older adults and individuals with underlying
chronic health problems
The primary reservoir is aquatic
birds, but viruses also circulate
among many other species, such
as pigs, horses, and seamammals8
• Classified into subtypes on the basis of haemagglutinin (H) and
neuraminidase (N) antigens on the surface of the viral envelope
• To date, 18 haemagglutinin subtypes and 11 neuraminidase
subtypes have been identified
• Only three haemagglutinin types (H1, H2, and H3) are
recognised to cause epidemic disease in humans
• Nomenclature includes the virus type and subtype, natural host
species, geographical origin, year of isolation, and strain number
(such as H1N1/A/duck/Alberta/35/76)7
A
Children are affected by influenza B infection
at a disproportionately higher rate among the
general population9 10
Mainly infects humansDivided into lineages on the basis of the haemagglutinin
glycoprotein
B
Affects individuals of all ages, but tends to
cause mild illness11
Mainly infects humansUnlike influenza A or B, which have two glycoproteins (HA and
NA), influenza C has only one glycoprotein (HEF)
C
Not known to cause human disease5Mainly infects pigs and cattleLittle known about it, but is thought to be related to influenza C
viruses
D
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Table 2| Antigenic drift versus antigenic shift: implications for epidemics and pandemics
Antigenic shiftAntigenic drift
A sudden major change in the virus antigenicityAccumulation of mutations in genes that code for antibody binding sites on viruses
leading to emergence of new strains
From one or more virus strains (from genome reassortment)Only one virus strain (accumulation of point mutations)
Occurs occasionallyOccurs frequently
Gives rise to pandemics, which occur irregularly and unpredictably due to a
lack of immunity to the new strain in the human population
Usually responsible for seasonal influenza epidemics and affects effectiveness of
influenza vaccine
Only occurs in influenza virus AOccurs in influenza virus A, B, and C
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Table 3| Responding to influenza cases and clusters or outbreaks by setting
Acute clinical
setting
Care home settingCommunity setting
Interventions Low risk patientsAt-risk patients
YesYes*Avoid contact with at-risk people and
exclude from work, school, or
childcare until asymptomatic
Avoid contact with other at-risk
people and exclude from work,
school, or childcare until
asymptomatic
Isolation of patients49 50
YesYesNot recommendedNot recommendedUse of PPE including surgical masks51 52
YesYesProvide advice on hand hygiene and
correct cough etiquette
Provide advice on hand hygiene and
correct cough etiquette
Implementation of rigorous infection
control procedures (hand hygiene; cough
etiquette; environmental cleaning and
waste disposal)49-51 53
YesYesYesYesSymptomatic management21
Recommended†Recommended†Not recommendedRecommendedAntiviral therapy for patients with
influenza12-54
YesYes‡Not recommendedYes‡Regular review to assess for clinical
deterioration12
*If not possible or practical, consider cohorting of patients as soon as possible.
†Consider post-exposure prophylaxis for other at-risk patients and residents in hospitals and care home settings.
‡Have low threshold for referring to secondary care.
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Figures
Fig 1 Symptoms and complications of influenza. Complicated influenza is defined as an infection that requires hospital
admission12
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Fig 2 Circulating influenza viruses reported to WHO through global laboratory surveillance systems for selected countries:
2015-16. Data from WHO FluNet Interactive https://pmacp.shinyapps.io/Influenza_isolates/
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